During the corresponding conference call, ICON CEO, defendant Stephen Cutler, revealed that two of ICON’s large pharmaceutical customers had materially curtailed upcoming FSP trial work due to ongoing ...
Icon delayed its fourth-quarter and 2025 financial results amid its ongoing accounting review, with preliminary findings suggesting the company's revenue for fiscal years 2023 and 2024 may have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results